돌아가기
Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
HRID 227686생성일: 2026년 10월 24일

1-Fluoronaphthalene → N,N-Dimethyl-3-((naphthalen-1-yl)oxy)-3-(thiophen-2-yl)propan-1-amine

https://huagongshe.com/ko/reaction/227686

반응식

참여 물질

역할이름HCID투입량
반응물1-FluoronaphthaleneHCID 9450—
반응물DuloxetineHCID 60835—
반응물2,3:4,6-di-O-Isopropylidene-2-keto-L-gulonic acidHCID 65420—
반응물(S)-mandelic acidHCID 439616—
반응물3-(Dimethylamino)-1-(2-thienyl)-1-propanolHCID 11586409—
생성물N,N-Dimethyl-3-((naphthalen-1-yl)oxy)-3-(thiophen-2-yl)propan-1-amineHCID 11573192—

반응 단계

The preparation of the enantiomerically pure duloxetine intermediate (S)-AT-OL by its chiral resolution is exemplified in U.S. Pat. No. 5,362,886 (U.S. '886) and in WO 2004/031168, by the use of (S)-(+)-mandelic acid and (−)-2,3:4,6-Di-O-isopropylidene-2-keto-L-gulonic acid, respectively. The U.S. '886 patent describes the preparation of duloxetine by the chiral resolution of N,N-Dimethyl-3-(2-thienyl)-3-hydroxypropanamine (rac-AT-OL) with (S)-mandelic acid (Stage a), its reaction with fluoronaphtalene (Stage b) to give N,N-Dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine (DNT), demethylation with phenyl chloroformate (Stage c), basic hydrolysis in the presence of (Stage d), and acidification (Stage e) in accordance with the following Scheme 1.

출처 및 근거

DOI10.6084/m9.figshare.5104873.v1
특허 번호US07560573B2
출처 데이터셋uspto-grants-2009_07
ORD IDord-b4e13c2f94f946e48272c9a7635dea3d
출처 메모uspto-grants-2009_07